Androgen Suppression With Stereotactic Body or External Beam Radiation Therapy (ASSERT)

Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.

Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.

The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.